Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study/Experiment 2

From BugSigDB


Reviewed Marked as Reviewed by ChiomaBlessing on 2023-12-21

Curated date: 2023/12/21

Curator: ChiomaBlessing

Revision editor(s): ChiomaBlessing

Subjects

Location of subjects
China
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Buccal mucosa Buccal mucosa,buccal mucosa
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Response to immunochemotherapy Response to immunochemotherapy,response to immunochemotherapy
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Non-responders
Group 1 name Corresponds to the case (exposed) group for case-control studies
Responders
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients in the clinical response group treated by immune checkpoint inhibitors therapy (defined by radiographic evidence of complete response, partial response or stable disease per RECIST 1.1 criteria for at least 6 months)

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
LEfSe
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
increased